Gold prices slid below $4,000/oz amid profit-taking on Gaza ceasefire
Director Leon O. Moulder Jr. of Zenas BioPharma, Inc. (NASDAQ:ZBIO) acquired 36,928 shares of common stock on October 7, 2025, at a price of $20.85 per share, for a total transaction value of $769,948. The stock, currently trading at $27.76, has shown remarkable momentum with a 32.51% gain in the past week alone, according to InvestingPro data.
The purchase was made by The Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008, of which Moulder is a Trustee. Following the transaction, the trust directly holds 36,928 shares. Moulder also indirectly holds 1,672,039 shares through Tellus BioVentures LLC and directly holds 266,155 shares. The timing appears strategic, as the company’s stock is trading near its 52-week high of $28.72, with analyst price targets ranging from $24 to $45.
Moulder is the Chief Executive Officer and Chairman of the Board of Directors for Zenas BioPharma, which has a market capitalization of $1.09 billion. InvestingPro subscribers can access 13 additional investment tips and comprehensive financial metrics to evaluate this biotech company’s potential.
In other recent news, Zenas Biopharma announced a significant licensing agreement with InnoCare Pharma, securing global rights to develop and commercialize three autoimmune product candidates. This includes orelabrutinib, a BTK inhibitor currently in Phase 3 development for multiple sclerosis, with the total potential value of the deal exceeding $2 billion. The agreement involves Zenas paying InnoCare up to $100 million in upfront and near-term milestone payments, along with up to 7 million shares of Zenas common stock. H.C. Wainwright has maintained a Buy rating for Zenas Biopharma, citing the expansion of the company’s pipeline due to this agreement. The firm also set a price target of $30.00 for the company’s stock.
Additionally, Zenas Biopharma has secured rights to a novel oral IL-17AA/AF inhibitor and an oral brain-penetrant TYK2 inhibitor as part of the agreement. Meanwhile, Zeta Network Group has entered a strategic partnership with SOLV Foundation to advance its Bitcoin-centric financial initiatives. This partnership aims to leverage SOLV’s platform, which holds $2.5 billion in total value locked, to enhance the efficiency of Zeta’s Bitcoin holdings. Under the agreement, Zeta’s Bitcoin assets will be managed by a regulated third-party custodian, ensuring transparency and institutional-grade auditability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.